Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 150

1.

Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record.

Ramirez AH, Shi Y, Schildcrout JS, Delaney JT, Xu H, Oetjens MT, Zuvich RL, Basford MA, Bowton E, Jiang M, Speltz P, Zink R, Cowan J, Pulley JM, Ritchie MD, Masys DR, Roden DM, Crawford DC, Denny JC.

Pharmacogenomics. 2012 Mar;13(4):407-18. doi: 10.2217/pgs.11.164. Epub 2012 Feb 13.

2.

Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study.

Perera MA, Cavallari LH, Limdi NA, Gamazon ER, Konkashbaev A, Daneshjou R, Pluzhnikov A, Crawford DC, Wang J, Liu N, Tatonetti N, Bourgeois S, Takahashi H, Bradford Y, Burkley BM, Desnick RJ, Halperin JL, Khalifa SI, Langaee TY, Lubitz SA, Nutescu EA, Oetjens M, Shahin MH, Patel SR, Sagreiya H, Tector M, Weck KE, Rieder MJ, Scott SA, Wu AH, Burmester JK, Wadelius M, Deloukas P, Wagner MJ, Mushiroda T, Kubo M, Roden DM, Cox NJ, Altman RB, Klein TE, Nakamura Y, Johnson JA.

Lancet. 2013 Aug 31;382(9894):790-6. doi: 10.1016/S0140-6736(13)60681-9. Epub 2013 Jun 5.

3.

Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans.

Limdi NA, Arnett DK, Goldstein JA, Beasley TM, McGwin G, Adler BK, Acton RT.

Pharmacogenomics. 2008 May;9(5):511-26. doi: 10.2217/14622416.9.5.511.

4.

Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy.

Limdi NA, Wiener H, Goldstein JA, Acton RT, Beasley TM.

Blood Cells Mol Dis. 2009 Jul-Aug;43(1):119-28. doi: 10.1016/j.bcmd.2009.01.019. Epub 2009 Mar 17.

5.

Validation of a proposed warfarin dosing algorithm based on the genetic make-up of Egyptian patients.

Ekladious SM, Issac MS, El-Atty Sharaf SA, Abou-Youssef HS.

Mol Diagn Ther. 2013 Dec;17(6):381-90. doi: 10.1007/s40291-013-0046-3.

PMID:
23839801
6.

The future of warfarin pharmacogenetics in under-represented minority groups.

Cavallari LH, Perera MA.

Future Cardiol. 2012 Jul;8(4):563-76. doi: 10.2217/fca.12.31. Review.

7.

Factors influencing warfarin dose requirements in African-Americans.

Momary KM, Shapiro NL, Viana MA, Nutescu EA, Helgason CM, Cavallari LH.

Pharmacogenomics. 2007 Nov;8(11):1535-44.

PMID:
18034618
8.

CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing.

Scott SA, Jaremko M, Lubitz SA, Kornreich R, Halperin JL, Desnick RJ.

Pharmacogenomics. 2009 Aug;10(8):1243-55. doi: 10.2217/pgs.09.71.

9.

Extending and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare variants of CYP2C9.

Sagreiya H, Berube C, Wen A, Ramakrishnan R, Mir A, Hamilton A, Altman RB.

Pharmacogenet Genomics. 2010 Jul;20(7):407-13. doi: 10.1097/FPC.0b013e328338bac2. Erratum in: Pharmacogenet Genomics. 2010 Oct;20(10):645. Sagrieya, Hersh [corrected to Sagreiya, Hersh].

10.

A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans.

Voora D, Koboldt DC, King CR, Lenzini PA, Eby CS, Porche-Sorbet R, Deych E, Crankshaw M, Milligan PE, McLeod HL, Patel SR, Cavallari LH, Ridker PM, Grice GR, Miller RD, Gage BF.

Clin Pharmacol Ther. 2010 Apr;87(4):445-51. doi: 10.1038/clpt.2009.291. Epub 2010 Mar 3.

11.

Poor warfarin dose prediction with pharmacogenetic algorithms that exclude genotypes important for African Americans.

Drozda K, Wong S, Patel SR, Bress AP, Nutescu EA, Kittles RA, Cavallari LH.

Pharmacogenet Genomics. 2015 Feb;25(2):73-81. doi: 10.1097/FPC.0000000000000108.

12.

VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans.

Limdi NA, Beasley TM, Crowley MR, Goldstein JA, Rieder MJ, Flockhart DA, Arnett DK, Acton RT, Liu N.

Pharmacogenomics. 2008 Oct;9(10):1445-58. doi: 10.2217/14622416.9.10.1445.

13.

Effect of CYP2C9, VKORC1, CYP4F2 and GGCX genetic variants on warfarin maintenance dose and explicating a new pharmacogenetic algorithm in South Indian population.

Krishna Kumar D, Shewade DG, Loriot MA, Beaune P, Balachander J, Sai Chandran BV, Adithan C.

Eur J Clin Pharmacol. 2014 Jan;70(1):47-56. doi: 10.1007/s00228-013-1581-x. Epub 2013 Sep 10.

PMID:
24019055
14.

Race influences warfarin dose changes associated with genetic factors.

Limdi NA, Brown TM, Yan Q, Thigpen JL, Shendre A, Liu N, Hill CE, Arnett DK, Beasley TM.

Blood. 2015 Jul 23;126(4):539-45. doi: 10.1182/blood-2015-02-627042. Epub 2015 May 29.

15.

New genetic variant that might improve warfarin dose prediction in African Americans.

Schelleman H, Brensinger CM, Chen J, Finkelman BS, Rieder MJ, Kimmel SE.

Br J Clin Pharmacol. 2010 Sep;70(3):393-9. doi: 10.1111/j.1365-2125.2010.03709.x.

16.

Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.

Carlquist JF, Horne BD, Muhlestein JB, Lappé DL, Whiting BM, Kolek MJ, Clarke JL, James BC, Anderson JL.

J Thromb Thrombolysis. 2006 Dec;22(3):191-7.

PMID:
17111199
17.

Genetic and clinical predictors of warfarin dose requirements in African Americans.

Cavallari LH, Langaee TY, Momary KM, Shapiro NL, Nutescu EA, Coty WA, Viana MA, Patel SR, Johnson JA.

Clin Pharmacol Ther. 2010 Apr;87(4):459-64. doi: 10.1038/clpt.2009.223. Epub 2010 Jan 13.

PMID:
20072124
18.

Copy number variation and warfarin dosing: evaluation of CYP2C9, VKORC1, CYP4F2, GGCX and CALU.

Scott SA, Patel M, Martis S, Lubitz SA, van der Zee S, Yoo C, Edelmann L, Halperin JL, Desnick RJ.

Pharmacogenomics. 2012 Feb;13(3):297-307. doi: 10.2217/pgs.11.156. Epub 2011 Dec 21.

19.

The missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans.

Perera MA, Gamazon E, Cavallari LH, Patel SR, Poindexter S, Kittles RA, Nicolae D, Cox NJ.

Clin Pharmacol Ther. 2011 Mar;89(3):408-15. doi: 10.1038/clpt.2010.322. Epub 2011 Jan 26.

20.

Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups.

Scott SA, Khasawneh R, Peter I, Kornreich R, Desnick RJ.

Pharmacogenomics. 2010 Jun;11(6):781-91. doi: 10.2217/pgs.10.49.

Items per page

Supplemental Content

Write to the Help Desk